Johnson & Johnson (NYSE:JNJ) has been given an average rating of “Buy” by the nine brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $190.38.
A number of research analysts recently commented on the company. Credit Suisse Group set a $193.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Monday, June 7th. Morgan Stanley assumed coverage on Johnson & Johnson in a research note on Friday, May 28th. They issued an “overweight” rating and a $187.00 target price for the company.
Shares of JNJ stock traded up $0.84 during trading hours on Friday, reaching $170.33. 253,334 shares of the company’s stock were exchanged, compared to its average volume of 6,223,537. Johnson & Johnson has a fifty-two week low of $133.65 and a fifty-two week high of $173.65. The company has a market capitalization of $448.55 billion, a PE ratio of 30.07, a P/E/G ratio of 2.71 and a beta of 0.71. The business’s fifty day simple moving average is $167.25. The company has a quick ratio of 1.04, a current ratio of 1.28 and a debt-to-equity ratio of 0.46.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th will be given a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Monday, August 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 52.80%.
A number of large investors have recently made changes to their positions in JNJ. OLD Mission Capital LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth $362,000. Sage Mountain Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $525,000. Ironwood Wealth Management LLC. grew its holdings in shares of Johnson & Johnson by 1,559.2% during the fourth quarter. Ironwood Wealth Management LLC. now owns 7,400 shares of the company’s stock worth $1,165,000 after purchasing an additional 6,954 shares during the last quarter. Mattern Capital Management LLC grew its holdings in shares of Johnson & Johnson by 3.5% during the fourth quarter. Mattern Capital Management LLC now owns 30,032 shares of the company’s stock worth $4,726,000 after purchasing an additional 1,014 shares during the last quarter. Finally, United Bank grew its holdings in shares of Johnson & Johnson by 46.4% during the fourth quarter. United Bank now owns 9,863 shares of the company’s stock worth $1,552,000 after purchasing an additional 3,127 shares during the last quarter. Hedge funds and other institutional investors own 66.60% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Article: How does a reverse stock split work?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.